GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Propanc Biopharma Inc (OTCPK:PPCB) » Definitions » Cyclically Adjusted Price-to-FCF

Propanc Biopharma (Propanc Biopharma) Cyclically Adjusted Price-to-FCF : (As of May. 24, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Propanc Biopharma Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Propanc Biopharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Propanc Biopharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Propanc Biopharma Cyclically Adjusted Price-to-FCF Chart

Propanc Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Propanc Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Propanc Biopharma's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Propanc Biopharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Propanc Biopharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Propanc Biopharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Propanc Biopharma's Cyclically Adjusted Price-to-FCF falls into.



Propanc Biopharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Propanc Biopharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Propanc Biopharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.002/127.6062*127.6062
=-0.002

Current CPI (Mar. 2024) = 127.6062.

Propanc Biopharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.000 98.352 0.000
201409 0.000 98.816 0.000
201412 0.000 99.002 0.000
201503 0.000 99.187 0.000
201506 0.000 99.838 0.000
201509 0.000 100.302 0.000
201512 0.000 100.673 0.000
201603 0.000 100.488 0.000
201606 0.000 100.859 0.000
201609 0.000 101.602 0.000
201612 0.000 102.159 0.000
201703 0.000 102.624 0.000
201706 0.000 102.809 0.000
201709 0.000 103.460 0.000
201712 0.000 104.110 0.000
201803 0.000 104.574 0.000
201806 0.000 104.945 0.000
201809 0.000 105.410 0.000
201812 0.000 105.967 0.000
201903 0.000 105.967 0.000
201906 0.000 106.617 0.000
201909 0.000 107.174 0.000
201912 0.000 107.917 0.000
202003 0.000 108.289 0.000
202006 0.000 106.246 0.000
202009 -180.000 107.917 -212.840
202012 -261.000 108.846 -305.984
202103 -156.000 109.496 -181.801
202106 -16.857 110.332 -19.496
202109 -18.037 111.168 -20.704
202112 -4.571 112.654 -5.178
202203 -4.758 115.069 -5.276
202206 -1.868 117.112 -2.035
202209 -1.074 119.248 -1.149
202212 -0.234 121.477 -0.246
202303 -0.100 123.148 -0.104
202306 -0.030 124.170 -0.031
202309 -0.030 125.656 -0.030
202312 -0.010 126.399 -0.010
202403 -0.002 127.606 -0.002

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Propanc Biopharma  (OTCPK:PPCB) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Propanc Biopharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Propanc Biopharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Propanc Biopharma (Propanc Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
302, 6 Butler Street, Cambwerwell, VIC, AUS, 3124
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
Executives
Josef Zelinger director 59 SEYMOUR ROAD, ELSTERNWICK C3 3185
Carlo M Campiciano officer: CFO & Secretary C/O. PROPANC BIOPHARMA,INC., 302, 6 BUTLER STREET, CAMBERWELL C3 3124
Julian Norman Kenyon director BEECHWOOD, EMBLEY LANE, EAST WELLOW, ROMSEY HAMPSHIRE X0 SO516DN
James Andrew Nathanielsz director, officer: CEO, CFO, Secretary, Treasurer 1/76 SUMMERHILL ROAD, GLEN IRIS, VICTORIA C3 3146